



IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

15 December 2020

Issue of unlisted performance rights and options under Equity Incentive Plan

MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer advises that it has today lodged an Appendix 3G for the issue of 5,000,000 Unlisted Performance Rights and 3,000,000 Unlisted Performance Options.

Following the approval of the Equity Incentive Plan at the Company's Annual General Meeting held on 29 July 2020, the Board of Directors have approved the issuance of Unlisted Performance Rights and Options to Mr. Geoff Hollis, the Company's CFO and Company Secretary, who is eligible to participate in the Company's incentive scheme.

The performance rights are in three tranches and are dependent on achieving certain organisational milestones as outlined within the Appendix 3G. The performance rights will expire on 30 November 2023.

The performance options have an exercise price of \$0.14 per share vesting in three tranches over three years with expiry dates between 30 November 2025 and 30 November 2028.

-ENDS

About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

For further information please visit www.imagionbiosystems.com

Authorisation & Additional information

This announcement was authorised by the Disclosure Committee of Imagion Biosystems Limited

U.S. Media Contact:

Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630

Australian Media & Investor Relations:

Kyahn Williamson, WE Communications
We-AUImagionBiosystems@we-worldwide.com
+61 (0) 401018828